New substances are treating infections by activating the immune system

Febrile neutropenia is a common,
life-threatening
complication of chemotherapy
Gut barrier Injury and Neutrophil
depletion puts patients at risk for
bacteremia and sepsis
AKTHELIA'S DRUG CANDIDATE KNOCKS OUT
BACTERAEMIA BY STRENGTHENING
INNATE GUT BARRIER DEFENSES
eliminating the need for prophylactiC antibiotics
reducing risk of serious adverse events,
antimicrobial resistance and
microbiome dysbiosis

HOME
News
New substances are treating infections by activating the immune system

New substances are treating infections by activating the immune system

Interview with Peter Bergman

January 15, 2019

2018, Peter Bergman, Akthelia's clinical advisor, received research support from the Swedish Foundation To Prevent Antibiotic Resistance. The foundation's website featured an interview with Peter which can be found here.

Febrile neutropenia is a common, life-threatening complication of chemotherapy

Gut barrier Injury and Neutrophil depletion puts patients at risk for bacteremia and sepsis

AKTHELIA'S DRUG CANDIDATE KNOCKS OUT BACTERAEMIA BY STRENGTHENING INNATE GUT BARRIER DEFENSES

eliminating the need for prophylactiC antibiotics

reducing risk of serious adverse events, antimicrobial resistance and microbiome dysbiosis

New substances are treating infections by activating the immune system

Interview with Peter Bergman

Febrile neutropenia is a common,
life-threatening
complication of chemotherapy

Gut barrier Injury and Neutrophil
depletion puts patients at risk for
bacteremia and sepsis

AKTHELIA'S DRUG CANDIDATE KNOCKS OUT
BACTERAEMIA BY STRENGTHENING
INNATE GUT BARRIER DEFENSES

reducing risk of serious adverse events,
antimicrobial resistance and
microbiome dysbiosis